Safety-First Pension Funds, Governance, and Market Risk: Evidence from China’s A-Share Market
Financial Economics Research · 17.04.2026 · 3 (2) · 108-119
DOI: 10.70267/fer.250302.108119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Financial Economics Research, online erschienen am 17.04.2026. Verfasst von Yun'e Xie. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This paper examines how Chinese public pension funds affect corporate governance and market risk in a state-capitalist setting. Using A-share firms from 2015 to 2024, we show that pension funds display an ESG screening effect ex ante and are followed by higher post-investment ESG scores. The effect, however, is concentrated in the governance pillar and is more than twice as large in SOEs as in private firms. Despite these governance gains, pension ownership is not associated with lower stock-return volatility. We interpret this pattern as governance-risk decoupling: pension funds appear to promote visible, compliance-oriented governance upgrades, but their small stakes and the retail-dominated market limit their ability to stabilize prices. The findings refine the universal-owner view by showing that, in transitional economies, state-backed patient capital may function more as administrative legitimacy than as a direct mechanism of market-risk reduction.
Zitieren
APA
Xie, Y. (2026). Safety-First Pension Funds, Governance, and Market Risk: Evidence from China’s A-Share Market. Financial Economics Research, 3(2), 108-119. https://doi.org/10.70267/fer.250302.108119
Vancouver
Xie Y. Safety-First Pension Funds, Governance, and Market Risk: Evidence from China’s A-Share Market. Financial Economics Research. 2026;3(2):108-119. doi:10.70267/fer.250302.108119
BibTeX
@article{Xie2026,
author = {Xie, Yun'e},
title = {Safety-First Pension Funds, Governance, and Market Risk: Evidence from China’s A-Share Market},
journal = {Financial Economics Research},
year = {2026},
volume = {3},
number = {2},
pages = {108--119},
doi = {10.70267/fer.250302.108119}
}
EUVIMED